Skip to content

Study on the therapeutic effect of dual plasma exchange system (DFPP) combined with "Bu Gan Li Zhi Tang" on fatty liver with severe hypertriglyceridemia and the mechanism of blood lipid oscillation balance

Study on the therapeutic effect of dual plasma exchange surgery combined with "Bugan Lizhi Tang" on severe hypertriglyceridemic fatty liver and the regulatory effect of HCBP6 protein

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076067
Enrollment
Unknown
Registered
2023-09-22
Start date
2021-06-20
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe high triglyceride fatty liver disease

Interventions

Observation group :Treat once with blood purification DFPP mode, supplemented by oral administration of traditional Chinese medicine "Bugan Lizhi Tang" for 24 weeks
control group:Using blood purification DFPP mode for treatment once, assisted by oral administration of bezafibrate for 24 weeks

Sponsors

Ankang Traditional Chinese Medicine Hospital Affiliated to Shaanxi University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) No history of alcohol consumption or alcohol consumption equivalent to less than 140g/week for males and less than 70g/week for females; (2) Excluding specific diseases that can lead to fatty liver, such as viral hepatitis, drug-induced liver disease, total parenteral nutrition, hepatolenticular degeneration, autoimmune liver disease, etc; (3) The manifestations of liver imaging meet the diagnostic criteria for diffuse fatty liver and there are no other reasons to explain; (4)Patients with metabolic syndrome components experience continuous increases in liver function ALT and/or AST, GGT, but not exceeding the normal upper limit by 5 times. (5) Triglycerides greater than 11.3 mmol/L.

Exclusion criteria

Exclusion criteria: 1) Alcoholic fatty liver disease; (2) Viral hepatitis (A, B, C, D, E); (3) Liver cirrhosis and primary liver cancer; (4) Pregnant and lactating women; Mental disorders, renal dysfunction, complications of diabetes, acute coronary syndrome and serious organic diseases; (5) Drug induced liver injury, autoimmune liver disease, hepatolenticular degeneration;

Design outcomes

Primary

MeasureTime frame
triglyceride;APO-A1;APO-B;LSM;

Secondary

MeasureTime frame
HCBP6 protein;uric acid;ALT;AST;HDL-C;URBC;Bun/SCr/eGFR;ALB;Traditional Chinese Medicine Syndrome Points;LDL-C;

Countries

China

Contacts

Public ContactXianwen Cheng

Ankang Traditional Chinese Medicine Hospital Affiliated to Shaanxi University of Traditional Chinese Medicine

807497738@qq.com+86 177 7292 8900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026